Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bengt Winblad

Showing results (501-510 of 538) with videos related to

Pageof 54
Sort By:
Dementia and Geriatric Cognitive Disorders|March 2, 2012
Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's diseaseMaria Eriksdotter-Jönhagen, Bengt Linderoth, Göran Lind, et al.
Alzheimer'S Research & Therapy|October 26, 2018
FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's diseasePetr Novak, Reinhold Schmidt, Eva Kontsekova, et al.
Alzheimer'S Research & Therapy|May 24, 2025
Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADCKristian S Frederiksen, Mercé Boada, Bruno Dubois, et al.
Nature Reviews. Neurology|December 17, 2014
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseasesAlberto Lleó, Enrica Cavedo, Lucilla Parnetti, et al.
Lancet (London, England)|April 25, 2006
Mild cognitive impairmentSerge Gauthier, Barry Reisberg, Michael Zaudig, et al.
Brain Communications|September 8, 2023
Alzheimer's disease biomarker profiling in a memory clinic cohort without common comorbiditiesMakrina Daniilidou, Francesca Eroli, Vilma Alanko, et al.
Cell Research|November 18, 2021
An App knock-in rat model for Alzheimer's disease exhibiting Aβ and tau pathologies, neuronal death and cognitive impairmentsKeliang Pang, Richeng Jiang, Wei Zhang, et al.
The Lancet. Neurology|December 14, 2016
Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trialPetr Novak, Reinhold Schmidt, Eva Kontsekova, et al.
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
Point of view: Challenges in implementation of new immunotherapies for Alzheimer's diseaseSandar Aye, Gunilla Johansson, Christoph Hock, et al.
Journal of Alzheimer'S Disease : JAD|August 23, 2021
A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease: Results from the MOPEAD ProjectAnders Wimo, Mark Belger, Jaka Bon, et al.
Pageof 54

Showing results (501-510 of 538) with videos related to

Sort By:
Pageof 54
Dementia and Geriatric Cognitive Disorders|March 2, 2012
Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's diseaseMaria Eriksdotter-Jönhagen, Bengt Linderoth, Göran Lind, et al.
Alzheimer'S Research & Therapy|October 26, 2018
FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's diseasePetr Novak, Reinhold Schmidt, Eva Kontsekova, et al.
Alzheimer'S Research & Therapy|May 24, 2025
Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADCKristian S Frederiksen, Mercé Boada, Bruno Dubois, et al.
Nature Reviews. Neurology|December 17, 2014
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseasesAlberto Lleó, Enrica Cavedo, Lucilla Parnetti, et al.
Lancet (London, England)|April 25, 2006
Mild cognitive impairmentSerge Gauthier, Barry Reisberg, Michael Zaudig, et al.
Brain Communications|September 8, 2023
Alzheimer's disease biomarker profiling in a memory clinic cohort without common comorbiditiesMakrina Daniilidou, Francesca Eroli, Vilma Alanko, et al.
Cell Research|November 18, 2021
An App knock-in rat model for Alzheimer's disease exhibiting Aβ and tau pathologies, neuronal death and cognitive impairmentsKeliang Pang, Richeng Jiang, Wei Zhang, et al.
The Lancet. Neurology|December 14, 2016
Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trialPetr Novak, Reinhold Schmidt, Eva Kontsekova, et al.
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
Point of view: Challenges in implementation of new immunotherapies for Alzheimer's diseaseSandar Aye, Gunilla Johansson, Christoph Hock, et al.
Journal of Alzheimer'S Disease : JAD|August 23, 2021
A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease: Results from the MOPEAD ProjectAnders Wimo, Mark Belger, Jaka Bon, et al.
Pageof 54